To overcome the EMP‐driven tumor deterioration, researchers have developed a range of small molecule inhibitors, immune‐related therapeutic approaches, and combination therapies to target the key biomarkers or crucial signaling pathways of EMP during tumor progression. Here, MAEA is linked to neoplasm.